Google Alert - lose weight

	lose weight As-it-happens update ⋅ April 2, 2026
	NEWS
	FDA approves Eli Lilly weight loss pill - YouTube YouTube The FDA approved a new GLP-1 drug from Eli Lilly. Dr. Jon LaPook breaks it down. "CBS Evening News" delivers the day's most important stories, ... Flag as irrelevant
	New research challenges what we know about yo-yo dieting - The Independent The Independent Weight loss and body fat. Our fat stores (known as adipose tissue) serve as our main energy (calorie) buffer when there's no food to provide that fuel ... Flag as irrelevant
	Lilly's weight loss pill wins FDA approval - EMJ GOLD EMJ Eli Lilly won FDA approval on 1 April 2026 for a once-daily oral GLP-1, orforglipron. Read more about the drug and its rollout. Flag as irrelevant
	Another GLP-1 weight loss pill gets FDA approval, and it has fewer restrictions on how it's used Scripps News The U.S. Food and Drug Administration on Wednesday approved the second GLP-1 pill for weight loss, adding another option to a rapidly growing ... Flag as irrelevant
	New weight loss pill offers needle-free option as demand for GLP-1 drugs surges - YouTube YouTube A new option is now available for millions of Americans looking to lose weight — without the need for injections. Flag as irrelevant
	FDA approves Lilly's Foundayo™ (orforglipron), the only GLP-1 pill for weight loss that can ... BioSpace "With Foundayo, we now have an oral option that delivered an average of 12.4% weight loss at the highest dose in clinical trials – addressing both the ... Flag as irrelevant
	New GLP-1 Pill Wins Speedy Approval for Weight Loss | MedPage Today MedPage Today Unlike oral semaglutide, orforglipron can be taken without restrictions on food and water intake. Flag as irrelevant
	Pricing and availability of Novo, Lilly's weight-loss drugs - Reuters Reuters The U.S. Food and Drug Administration has approved Eli Lilly's oral weight-loss drug, orforglipron, branded as Foundayo, making it the second pill ... Flag as irrelevant
See more results | Edit this alert

You have received this email because you have subscribed to Google Alerts. Unsubscribe | View all your alerts

Receive this alert as RSS feed

Send Feedback